Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen : provides free Aduhelm as U.S. clinics await Medicare payment

08/30/2021 | 06:00am EDT

Aug 30 (Reuters) - Biogen Inc is providing its controversial and expensive new Alzheimer's drug free of charge for some patients amid slow claim reviews by Medicare, according to sources familiar with the situation, including a doctor treating patients with the drug.

The development underscores the division among doctors about whether the $56,000-a-year drug helps patients and how uncertainty about reimbursement from Medicare, the U.S. government health plan for people over age 65, has held back prescriptions and sales.

Aduhelm, which is given as a monthly infusion, was approved by the U.S. Food and Drug Administration in June even though one of Biogen's two large clinical trials failed to show a benefit for patients diagnosed with the incurable mind-wasting disease.

In order to expedite treatment, Biogen has begun to provide Florida's First Choice Neurology with free-of-charge Aduhelm, according to Dr. Jeffrey Gelblum, a neurologist at the center's Aventura, Florida, operations.

"We have been using the Biogen access program - it is almost like a sample program - to get patients started," he told Reuters.

Biogen has said it has a number of plans in place to support patient access, but did not give further details.

Pharmaceutical companies can provide free medications through patient assistance programs, "however we have never heard of that for an injectable, infused drug," Steven Lucio, vice president at Vizient Inc, which works with about half of U.S. hospitals to buy drugs, said in an email.

James Chambers, a researcher at the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center in Boston, said providing free medications is a common strategy drugmakers use to boost patient prescription numbers.


A number of hospitals, as well as the Veterans Health Administration https://www.reuters.com/business/healthcare-pharmaceuticals/us-veterans-health-administration-turns-down-biogen-alzheimers-drug-2021-08-11, have said there is not enough evidence to justify widespread use of Aduhelm.

Several commercial insurers https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-alzheimers-drug-hits-roadblocks-with-some-hospitals-insurers-2021-07-15, including UnitedHealth Group Inc, the largest private insurer offering Medicare Advantage coverage to seniors, have said they are waiting for further direction from Medicare before covering the drug.

"Mainly because of the uncertainty around insurance coverage ... most doctors and systems are in a holding pattern," said Dr. Anton Porsteinsson, director of the University of Rochester Alzheimer's Disease Care, Research and Education Program, which is only using Aduhelm, also known as aducanumab, on patients enrolled in clinical trials.

A recent survey of 78 neurologists conducted by Morgan Stanley found that half were willing to prescribe Aduhelm, but nearly two-thirds don't think the FDA should have approved the drug. Just eight of the surveyed neurologists had prescribed Aduhelm and six of their Medicare claims had been paid as of early August.

Florida's First Choice has so far infused more than 30 patients with Aduhelm, but only the first doses for two patients were billed to Medicare - their second doses, and first doses for the others, were provided at no cost by Biogen, Dr. Gelblum said.

He said the clinic has been reimbursed by Medicare for the infusion component of claims, but not for the medication itself, although he expects that to happen within the next couple of weeks.

Because Alzheimer's is an age-related disease, around 85% of people eligible for Aduhelm are covered by Medicare, which recently launched https://www.reuters.com/business/healthcare-pharmaceuticals/us-starts-review-national-medicare-coverage-policy-biogens-aduhelm-2021-07-12 a nine-month process to determine standardized national coverage terms for the drug.

For now, the government health plan is processing Aduhelm claims on a case-by-case basis.

In addition to the medication itself, costs of administering Aduhelm include diagnostic testing for Alzheimer's and monitoring for side effects such as dangerous brain swelling.

Experts say Medicare could seek to lower https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-alzheimers-drug-slow-take-off-us-medicare-wrestles-with-coverage-2021-07-21 the therapy's cost to taxpayers by limiting access to the treatment, linking coverage to real-world evidence of patient outcomes, or setting a fixed payment that combines drug reimbursement with other costs related to the treatment.

Aduhelm, developed in partnership with Japan's Eisai Co Ltd , comes in two vial sizes of 300 milligrams (mg) and 170 mg. Patients are started out on a low dose, which is increased over time to the full dose of 10 mg per kg of a patient's weight.

Sales of the drug are forecast to total $81 million this year, $1.3 billion next year and $5.8 billion by 2026, according to Wall Street analysts polled by Refinitiv. (Reporting by Deena Beasley; editing by Caroline Humer and Jonathan Oatis)

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -2.00% 264.8 Delayed Quote.8.14%
EISAI CO., LTD. 0.02% 8039 End-of-day quote.9.05%
All news about BIOGEN INC.
10/22BIOGEN : Canaccord Genuity Adjusts Biogen PT to $390 From $423, Maintains Buy Rating
10/22BB BIOTECH AG : BB Biotech: i ricavi -2-
10/22PRESS RELEASE : BB Biotech: Gains realized -2-
10/21BIOGEN : UBS Adjusts Price Target on Biogen to $406 From $405, Maintains Buy Rating
10/21BIOGEN : Cowen Adjusts Biogen PT to $375 From $450, Maintains Outperform Rating
10/21BIOGEN : JPMorgan Adjusts Biogen's Price Target to $324 From $425, Maintains Neutral Ratin..
10/21BIOGEN : Morgan Stanley Adjusts Biogen's Price Target to $440 From $447, Maintains Overwei..
10/21BIOGEN : Oppenheimer Adjusts Price Target on Biogen to $390 from $450, Keeps Outperform Ra..
10/21BIOGEN : Needham Adjusts Price Target on Biogen to $386 from $398, Keeps Buy Rating
10/21BIOGEN : RBC Cuts Price Target on Biogen to $295 From $325, Maintains Sector Perform Ratin..
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2021 10 877 M - -
Net income 2021 1 657 M - -
Net Debt 2021 2 311 M - -
P/E ratio 2021 24,7x
Yield 2021 -
Capitalization 39 464 M 39 464 M -
EV / Sales 2021 3,84x
EV / Sales 2022 3,59x
Nbr of Employees 9 100
Free-Float 85,5%
Duration : Period :
Biogen Inc. Technical Analysis Chart | BIIB | US09062X1037 | MarketScreener
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 31
Last Close Price 264,80 $
Average target price 369,73 $
Spread / Average Target 39,6%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Alfred W. Sandrock Executive Vice President-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors